Does the CD40 rs1883832 C allele increase thyroid autoimmunity, especially in Graves' disease?

The CD40 rs1883832 (c.-1C>T) polymorphism is a functional single-nucleotide variant that plays a critical role in thyroid autoimmunity by modulating immune-cell costimulation.

Mechanistic pathways

• Translational efficiency: The rs1883832 C allele strengthens the Kozak consensus sequence in the 5′ untranslated region of the CD40 gene. This optimizes ribosomal recognition, increasing CD40 protein translation efficiency by 15% to 32% without changing mRNA levels.
• Costimulatory signaling: Upregulated cell-surface CD40 expression on antigen-presenting cells and B cells promotes robust CD40-CD40L interactions, amplifying downstream costimulatory cascades, B-cell activation, and pro-inflammatory signaling.

Clinical and autoantibody associations

• Graves' disease risk: Multiple meta-analyses and case-control studies establish the C allele (especially the CC genotype) as a significant susceptibility locus for Graves' disease, whereas the T allele serves as a protective variant.
• Autoantibody persistence: In Graves' disease patients, the C allele directly correlates with higher, more persistent titers of thyroid peroxidase (TPOAb), thyroglobulin (TgAb), and TSH receptor (TRAb) antibodies.
• Hashimoto's thyroiditis divergence: In contrast to the robust association with Graves' disease, genetic studies show no association with Hashimoto's thyroiditis, with odds ratios centering around a null value of 1.0. This disproves the concept of a "weaker" association, pointing instead to entirely distinct genetic architectures.

Bottom line

• Bottom line: The CD40 rs1883832 C allele enhances translational efficiency to drive costimulatory signaling and autoantibody production in Graves' disease, but it has no clinical or statistical association with Hashimoto's thyroiditis.